Pliant Therapeutics Reports $22.4 Million Net Loss in Q2 2026, Down from $43.3 Million Last Year

Pliant Therapeutics, Inc. reported a net loss of $22.4 million for the second quarter of 2026, a significant decrease from the $43.3 million loss recorded in the same period of the previous year. For the first half of 2026, the company’s net loss was $42.4 million, down from $99.5 million in the first half of 2025. The reduction in losses is attributed to a strategic shift in focus following the discontinuation of the bexotegrast program, which had previously incurred substantial expenses. As of June 30, 2026, Pliant's accumulated deficit stood at $901.8 million, with cash, cash equivalents, and short-term investments totaling $159.6 million.

Operating expenses for the second quarter of 2026 were $23.9 million, down from $45.6 million in the prior year, primarily due to a reduction in research and development costs, which fell to $16.7 million from $32.2 million. This decrease reflects the company's decision to streamline operations and focus on its lead product candidate, PLN-101095, which is currently in a Phase 1b clinical trial. General and administrative expenses also decreased to $7.1 million from $13.4 million, driven by workforce reductions implemented in 2025.

Pliant continues to advance its clinical programs, particularly the ongoing FORTIFY trial, which is evaluating PLN-101095 in combination with pembrolizumab for various solid tumors. The company reported strong enrollment in this trial, with interim data expected in 2027. Additionally, Pliant has made strategic appointments to its Board of Directors, enhancing its leadership team with experienced professionals in the biopharmaceutical sector.

The company’s operational metrics indicate a focus on efficiency and cost management, with a reduction in employee-related expenses due to workforce restructuring. As of June 30, 2026, Pliant had 61,920,154 shares of common stock outstanding. The company is classified as a non-accelerated filer and a smaller reporting company, which allows it to take advantage of certain scaled disclosure requirements. Looking ahead, Pliant anticipates continued investment in research and development, particularly for PLN-101095, while also preparing for potential future capital raises to support its operations and clinical development efforts.